UK rejects Gilead's CAR-T cancer cell therapy as too expensive

A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare cost agency NICE said on Tuesday.